Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

By sjmartinez • January 24, 2025

Gooderham MJ, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow H, Flack M, Korell J, Sofen H, Papp KA. Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis. J Invest Dermatol. 2025 Jan 21:S0022-202X(25)00034-X. doi: 10.1016/j.jid.2024.12.025. Epub ahead of print. PMID: 39848568.

Tags: clinical trials, Cytokines, Dermatology, Inflammatory skin diseases, Olive View DoM, psoriasis, Publications

Techniques and analytic workflow for spatial transcriptomics and its application to allergy and inflammation

Zhang H, Patrick MT, Zhao J, Zhai X, Liu J, Li Z, Gu Y, Welch J, Zhou X, Modlin R, Tsoi LC, Gudjonsson JE. Techniques[...]

Peterson H, Miao KL, Huang MY, Armstrong AW. Trending Psychiatric Comorbidities in Patients with Alopecia Areata in the United States from 2002 to 2019. J[...]

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment

Gorelick J, Nguyen A, Schneider SKR, Martel BC, Madsen DE, Armstrong AW. Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the[...]